Percheron Wins FDA Clearance for HMBD-002 Blood Cancer Trial
PER: $0.003 +0.00% · MC: $6M
The FDA has cleared Vanderbilt Health to proceed with an investigator-sponsored study of Percheron Therapeutics’ HMBD-002 alongside established treatments in patients with relapsed or refractory acute myeloid leukaemia or related disease. The study is planned to enrol up to 20 patients; Percheron will supply the drug and support the trial, with access to the resulting data. This advances the study beyond the earlier announcement of Vanderbilt’s role, but does not establish clinical benefit.

Comments